GLAXOSMITHKLINE PLC Form 6-K Current Event Report Filed 2021-05

SECURITIES AND EXCHANGE COMMISSION

FORM 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: 2021-05-06 | Period of Report: 2021-05-06 SEC Accession No. 0001654954-21-005202

(HTML Version on secdatabase.com)

FILER GLAXOSMITHKLINE PLC Mailing Address Business Address 980 GREAT WEST ROAD 980 GREAT WEST ROAD CIK:1131399| IRS No.: 000000000 | State of Incorp.:X0 BRENTFORD MIDDLESEX X0BRENTFORD MIDDLESEX X0 Type: 6-K | Act: 34 | File No.: 001-15170 | Film No.: 21897059 TW8 9GS TW8 9GS SIC: 2834 Pharmaceutical preparations 011442080475000

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2021

Commission File Number 001-15170

GlaxoSmithKline plc (Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F ......

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GlaxoSmithKline plc

GSK announces changes to its Board and Committees

GlaxoSmithKline plc today announces the following changes to its Board and Committee membership effective 6 May 2021.

As previously announced, Dr Anne Beal has joined the Board as an Independent Non-Executive Director. She has been appointed a member of the Corporate Responsibility Committee.

In addition, Charles Bancroft has been appointed a member of the Nominations & Corporate Governance and Science Committees. These appointments are in addition to his role as Chairman of the Audit & Risk Committee and membership of the Transformation & Separation Committee.

Note

1.From 6 May 2021 the Board of GSK comprises

Sir Jonathan Symonds Non-Executive Chairman Emma Walmsley Chief Executive Officer Chief Financial Officer

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Iain Mackay Chief Scientific Officer and President, R&D Dr Hal Barron Senior Independent Non-Executive Vindi Banga Director Charles Bancroft Independent Non-Executive Director Dr Anne Beal Independent Non-Executive Director Dr Vivienne Cox Independent Non-Executive Director Independent Non-Executive Director Lynn Elsenhans Independent Non-Executive Director Dr Jesse Goodman Independent Non-Executive Director Independent Non-Executive Director Dr Laurie Glimcher Urs Rohner

V A Whyte Company Secretary

6 May 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised. GlaxoSmithKline plc (Registrant)

Date: May 06, 2021

By:/s/ VICTORIA WHYTE ------

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc